A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1186 participants.
Also called NCT01809327
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,186 participants
- Registry
-
NCT01809327 -
2011-000400-17
-
- Other papers using this trial's data
- Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Czechia, Hungary, Mexico, Puerto Rico, Romania, Russia, Slovakia, South Africa, South Korea, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01809327. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-04 (actual); primary completion 2014-12-02 (actual). Results posted on 2016-01-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin 100 mg
- Intervention (Drug)
- Canagliflozin 300 mg
- Intervention (Drug)
- Metformin XR
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01809327- Content hash
f71efc37cd8cd57e12b4e2ef1cc7c02e6e32e5de0b95926741f7b05f2206a64b